tracken
Galapagos Aktie News
Neutral
Seeking Alpha
●
16 Tage alt
Galapagos NV ( GLPG ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Glenn Schulman Henry Gosebruch - CEO & Executive Director Aaron Cox - Chief Financial Officer Dan Grossman - Chief Strategy Officer Conference Call Participants Faisal Khurshid - Leerink Partners LLC, Research Division Brian Abrahams - RBC Capital Markets, Research Division Philip Nadeau - TD Cowen, Re...
Neutral
GlobeNewsWire
●
19 Tage alt
Oral presentation of GLPG5101 data from the ATALANTA-1 study in patients with high-risk relapsed/refractory mantle cell lymphoma
Neutral
GlobeNewsWire
●
30 Tage alt
Mechelen, Belgium ; October 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new in vitro pharmacological data from its selective TYK2 inhibitor, GLPG3667, currently in two Phase 3-enabling studies in dermatomyositis (DM) and systemic lupus erythematosus (SLE), at the American College of Rheumatology (ACR) Convergence 2025, taking place in Chicago...
Neutral
GlobeNewsWire
●
etwa ein Monat alt
Intention follows comprehensive strategic review process and would represent the optimal capital allocation pathway to support a stronger and sustainable future for Galapagos
Positiv
Reuters
●
etwa 2 Monate alt
Biotechnology firm Galapagos' board has received non-binding offers from consortia, mainly comprised of financial investors, for its cell-therapy business, the company said on Wednesday.
Neutral
GlobeNewsWire
●
etwa 2 Monate alt
Mechelen, Belgium ; October 1, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and its Board of Directors today issued the following statement:
Neutral
GlobeNewsWire
●
4 Monate alt
Mechelen, Belgium; August 7, 2025, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,800,000 subscription rights under a new subscription right plan.
Neutral
GlobeNewsWire
●
4 Monate alt
Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the United States Food and Drug Administration (FDA) has granted RMAT designation to GLPG5101, a second generation anti-CD19/4-1BB CAR-T product candidate for the treatment of relapsed/refractory mantle cell lymphoma (R/R MCL).
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
